Mineralys Therapeutics Stock (NASDAQ:MLYS)
Previous Close
$16.19
52W Range
$8.24 - $18.38
50D Avg
$14.63
200D Avg
$12.81
Market Cap
$1.04B
Avg Vol (3M)
$1.04M
Beta
-0.18
Div Yield
-
MLYS Company Profile
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.